All Updates

All Updates

icon
Filter
Partnerships
Genesis Therapeutics collaborates with Roche’s Subsidiary Genentech
AI Drug Discovery
Oct 18, 2020
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Oct 18, 2020

Genesis Therapeutics collaborates with Roche’s Subsidiary Genentech

Partnerships

  • Genesis Therapeutics, an AI drug discovery startup, has entered into a collaboration with Genentech, a wholly-owned biotechnology subsidiary of Roche Group, to support identification of new drug candidates across a range of diseases. 

  • Genentech will gain access to Genesis’ AI platform and other neural network algorithms that aim to predict how well molecules bind with moving protein chains.  This will help the company develop therapeutics for targets previously classified as undruggable. 

  • Genesis will receive an undisclosed amount as an upfront payment. The company may also receive preclinical, clinical and regulatory milestone payments and royalties on sales of therapeutics developed through the collaboration. 

  • Founded in 2019, Genesis Therapeutics is a Stanford University spinout company that claims to offer low cost AI drug discovery services. It secured seed funding of USD 4.1 million in November 2019.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.